Breast cancer risk cut by 35% in new clinical trial
Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday.
The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.
After a median follow-up of 14 months, patients treated with Trodelvy, a so-called antibody-drug conjugate, and Keytruda went 11.2 months without their cancer progressing, a measure known as progress-free survival. That compared with PFS of 7.8 months for those given the standard treatment of chemotherapy and Keytruda, researchers said.
Advertisement
3 Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.
REUTERS
Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to full results of the study presented at the American Society of Clinical Oncology scientific meeting in Chicago. The researchers said patients are still being followed to see if the regimen has an impact on overall survival.
Gilead previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 – the protein targeted by drugs like Keytruda – had met its goal.
Advertisement
The findings suggest that the combination of Trodelvy and Keytruda 'will likely become a new front-line standard of care in this setting,' Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a designated ASCO expert, said in a statement.
ASCO estimates that about 10% of breast cancers in the United States are triple-negative.
3 Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to the results.
Peakstock – stock.adobe.com
That tends to be more difficult to treat than hormone-sensitive subtypes, because it does not have the common biomarkers used to guide treatment, the tumors are often larger, and the recurrence rate is high.
Advertisement
The medical group said that about 40% of triple-negative breast cancers are also PD-L1 positive, making them candidates for Keytruda.
Antibody-drug conjugates like Trodelvy are designed to deliver an anti-cancer drug more precisely to malignant cells, causing less damage to healthy cells than chemotherapy.
3 Gilead is also conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.
REUTERS
Serious side effects for Trodelvy included neutropenia, a condition caused by cancer treatments that lower levels of infection-fighting white blood cells, reported in 43% of patients, and diarrhea in 10%. In the chemotherapy group, the incidence of neutropenia was 45%, while 16% of patients had anemia and 14% had low blood platelet counts.
Advertisement
Trodelvy is already approved for patients with advanced triple-negative breast cancer who had two or more prior therapies, and for previously treated hormone-receptor-positive, HER2-negative metastatic breast cancer.
Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 hours ago
- Yahoo
US judge blocks slashing of universities' federal funding from National Science Foundation
By Nate Raymond and Blake Brittain (Reuters) -A federal judge on Friday prevented the National Science Foundation from sharply cutting research funding provided to universities in the latest legal setback to efforts by U.S. President Donald Trump's administration to slash government support of research at major academic institutions. U.S. District Judge Indira Talwani in Boston invalidated a policy NSF adopted in May that limited the ability of universities to be reimbursed for administrative and facility costs that indirectly support grant-funded research, ruling that it was "arbitrary and capricious." Spokespeople for NSF and the White House did not immediately respond to requests for comment on the ruling. NSF, a $9 billion agency that funds scientific research, adopted the policy after having already canceled hundreds of grants out of step with the Republican president's priorities. His administration has also been freezing billions of dollars in government funding for numerous universities, including Harvard. NSF's policy, which was announced on May 2, set a cap on how much grant funding could go to cover indirect costs. NSF said funding for such costs could equal no more than 15% of the funding for direct research costs, regardless of what the costs actually were at universities. Historically, universities had negotiated with NSF and other agencies over the rate at which indirect costs could be reimbursed. The cap meant that for every $100 in funding going directly to a research grant award, universities would receive just $15 to cover overhead, such as the costs of maintaining lab space and paying for electricity and staff. The Trump administration said it sought through the policy to rein in spending on administrative overhead, which had grown to consume $1.07 billion of NSF's annual $4.22 billion grant-making budget for higher education institutions. That rate, though, is significantly lower than the indirect cost that many of the 69 research universities belonging to Association of American Universities had negotiated, which was often in the 50% to 65% range, the group's lawyers said. Talwani, an appointee of Democratic President Barack Obama, said in her Friday decision that the administration's 15% rate was unlawful. The association along with two other academic trade groups and 13 schools sued in May to block the policy, after earlier convincing judges in Boston to block similar funding cuts at the National Institutes of Health and U.S. Department of Energy. The association did not immediately respond to a request for comment on the Friday decision. Among the schools that challenged NSF's funding cuts were the Massachusetts Institute of Technology, Princeton University, Brown University, the University of California, Carnegie Mellon University, Cornell University, the University of Michigan and the University of Pennsylvania. They argued that NSF's action, if allowed to stand, "will badly undermine scientific research at America's universities and erode our nation's enviable status as a global leader in scientific research and innovation." The U.S. Department of Defense has since also adopted a 15% cap, which a judge on Tuesday temporarily blocked pending a hearing on July 2. He did so a day after a different judge in Boston ordered NIH to reinstate hundreds of grants for research on diversity-related topics nixed as part of the administration's purge of initiatives viewed as supporting "diversity, equity and inclusion."
New York Times
20 hours ago
- New York Times
The Waste Musk Created
On the edge of a lush jungle here in West Africa, the heavy metal doors of a warehouse creak open. Inside are boxes piled high with millions of doses of medicines donated by Merck and other pharmaceutical companies for a United States aid program. Yet the medications are gathering dust, and some are approaching their expiration dates and may have to be destroyed, at immense expense. It's an excellent example of the waste that President Trump claims was rife in the United States Agency for International Development. ('Absolutely obscene,' as he put it in February.) But this waste of drugs exists only because his administration shut down U.S.A.I.D. and canceled plans to distribute these medicines, even though the pills cost America nothing and are ready to use. Each tax dollar invested in mass administration of drugs like these leverages $26 in donated medicines, making the effort astoundingly cost-effective. One of the medications languishing in this warehouse is sufficient to protect 7.6 million children and adults from a parasitic disease called river blindness. Other donated medicines in the warehouse would rid more than two million children of worms, plus protect 1.4 million kids from a debilitating parasitic ailment called schistosomiasis that causes pain, weakness and bloody urine. These medicines also have the side benefit of protecting against worms that cause elephantiasis, a disfiguring and humiliating ailment. 'People come to ask for these drugs,' Tamba Koroma, the warehouse's watchman, told me. 'We tell them we can't distribute them.' Want all of The Times? Subscribe.
Yahoo
a day ago
- Yahoo
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron and Scholar Rock. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week. Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to preserve muscle will grow with the use of GLP-1 drugs for obesity, said TD Cowen analyst Tyler Van Buren. Doctors have raised concerns that patients may experience a decrease in overall strength due to muscle loss associated with Zepbound and Wegovy, while experts suggest that more muscle can help patients maintain long-term weight loss. Van Buren said that the first such treatment could launch by 2028, although regulatory challenges remain because these treatments must demonstrate additional health benefits to secure approval. "We believe quality of weight loss and lean mass preservation ... is far too important for long-term health outcomes to be ignored and that this will be figured out," Van Buren said. Some of the new drugs target the myostatin protein, which is associated with muscle growth, and are expected to see broader use due to their superior safety profile, capturing the majority of the market share, Van Buren said. Other drugs target activin, a protein with multiple biological functions. Van Buren said that activin-based drugs will be reserved for patients at higher risk of losing strength, forecasting sales of about $5 billion by 2035. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
